18.55
price up icon0.38%   0.07
pre-market  プレマーケット:  18.30   -0.25   -1.35%
loading
前日終値:
$18.48
開ける:
$18.51
24時間の取引高:
2.17M
Relative Volume:
1.31
時価総額:
$1.64B
収益:
$217.42M
当期純損益:
$-243.25M
株価収益率:
-6.6364
EPS:
-2.7952
ネットキャッシュフロー:
$-278.35M
1週間 パフォーマンス:
+4.86%
1か月 パフォーマンス:
-8.30%
6か月 パフォーマンス:
-10.47%
1年 パフォーマンス:
+85.69%
1日の値動き範囲:
Value
$18.25
$18.62
1週間の範囲:
Value
$17.31
$18.62
52週間の値動き範囲:
Value
$8.585
$25.59

Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile

Name
名前
Syndax Pharmaceuticals Inc
Name
セクター
Healthcare (1107)
Name
電話
781-419-1400
Name
住所
730 THIRD AVENUE, NEW YORK, MA
Name
職員
298
Name
Twitter
@syndax
Name
次回の収益日
2026-08-03
Name
最新のSEC提出書
Name
SNDX's Discussions on Twitter

Compare SNDX vs VRTX, REGN, ARGX, ALNY, RVMD

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
SNDX icon
SNDX
Syndax Pharmaceuticals Inc
18.55 1.64B 217.42M -243.25M -278.35M -2.7952
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
453.17 114.33B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
614.73 64.47B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
878.49 54.99B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
281.90 38.42B 4.29B 577.22M 641.34M 4.2086
RVMD icon
RVMD
Revolution Medicines Inc
156.58 34.03B 742.00K -1.37B -1.07B -7.0731

Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-10-16 再開されました H.C. Wainwright Buy
2025-09-10 再開されました Stifel Buy
2025-09-04 再開されました Guggenheim Buy
2025-08-05 繰り返されました BTIG Research Buy
2025-07-10 開始されました Goldman Buy
2024-10-24 開始されました UBS Buy
2024-06-28 開始されました Jefferies Buy
2024-01-31 ダウングレード Scotiabank Sector Outperform → Sector Perform
2023-12-22 開始されました Mizuho Buy
2023-10-25 開始されました BofA Securities Buy
2023-10-11 開始されました Goldman Buy
2023-07-27 開始されました Scotiabank Sector Outperform
2023-07-11 開始されました Guggenheim Buy
2023-04-17 再開されました BTIG Research Buy
2023-01-31 開始されました Stifel Buy
2023-01-03 開始されました JP Morgan Overweight
2022-07-28 再開されました B. Riley Securities Buy
2022-04-11 開始されました H.C. Wainwright Buy
2022-02-15 開始されました Goldman Buy
2021-06-04 再開されました Robert W. Baird Outperform
2021-05-25 開始されました Citigroup Buy
2021-02-18 開始されました B. Riley Securities Buy
2020-12-03 開始されました Stifel Buy
2020-05-22 アップグレード Citigroup Neutral → Buy
2020-05-22 ダウングレード H.C. Wainwright Buy → Neutral
2020-05-18 ダウングレード Citigroup Buy → Neutral
2020-05-11 繰り返されました H.C. Wainwright Buy
2020-03-04 開始されました Barclays Overweight
2020-01-13 繰り返されました H.C. Wainwright Buy
2019-03-08 繰り返されました H.C. Wainwright Buy
2019-01-04 開始されました Robert W. Baird Outperform
2018-01-05 開始されました B. Riley FBR, Inc. Buy
2017-03-16 開始されました FBR & Co. Outperform
2017-03-02 開始されました Instinet Buy
2016-10-07 開始されました Guggenheim Buy
2016-03-28 開始されました Citigroup Buy
2016-03-28 開始されました JMP Securities Mkt Outperform
2016-03-28 開始されました Morgan Stanley Overweight
すべてを表示

Syndax Pharmaceuticals Inc (SNDX) 最新ニュース

pulisher
Jun 15, 2026

Syndax Pharmaceuticals Inc at TD Cowen Oncology Innovation Summit (Virtual) Transcript - GuruFocus

Jun 15, 2026
pulisher
Jun 15, 2026

Syndax Pharmaceuticals Inc Annual Shareholders Meeting Transcript - GuruFocus

Jun 15, 2026
pulisher
Jun 14, 2026

Eventide Asset Management LLC Has $26.01 Million Stock Holdings in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat

Jun 14, 2026
pulisher
Jun 13, 2026

Syndax Pharmaceuticals (SNDX) Is Up 5.2% After Strong All-Oral Revuforj SAVE Trial DataWhat's Changed - Yahoo Finance

Jun 13, 2026
pulisher
Jun 13, 2026

Voss Capital LP Buys Shares of 125,000 Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat

Jun 13, 2026
pulisher
Jun 13, 2026

Rhenman & Partners Asset Management AB Sells 87,000 Shares of Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat

Jun 13, 2026
pulisher
Jun 12, 2026

SNDX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $40 - GuruFocus

Jun 12, 2026
pulisher
Jun 12, 2026

Syndax (SNDX) CMO sells 65,515 shares, retains 60,885 and large options - Stock Titan

Jun 12, 2026
pulisher
Jun 12, 2026

SNDX (NASDAQ) Rule 144 notice: Director-linked sale of 31,235 shares - Stock Titan

Jun 12, 2026
pulisher
Jun 12, 2026

symbol__ Stock Quote Price and Forecast - CNN

Jun 12, 2026
pulisher
Jun 12, 2026

SNDX Stock Price, Quote & Chart - ChartMill

Jun 12, 2026
pulisher
Jun 11, 2026

[144] Syndax Pharmaceuticals Inc SEC Filing - Stock Titan

Jun 11, 2026
pulisher
Jun 11, 2026

Syndax showcases revuforj (revumenib) data at EHA 2026 - grafa.com

Jun 11, 2026
pulisher
Jun 11, 2026

Syndax (SNDX) Reveals Encouraging Results from SAVE Trial for AM - GuruFocus

Jun 11, 2026
pulisher
Jun 11, 2026

Syndax Pharmaceuticals: The Duration Expansion Story Is Being Underpriced (NASDAQ:SNDX) - Seeking Alpha

Jun 11, 2026
pulisher
Jun 11, 2026

Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026 - The Manila Times

Jun 11, 2026
pulisher
Jun 11, 2026

Leukemia drug revumenib shows up to 97% remission in EHA 2026 data - Stock Titan

Jun 11, 2026
pulisher
Jun 11, 2026

Syndax Pharmaceuticals Announces Publication of Save Data on Revuforj in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML - marketscreener.com

Jun 11, 2026
pulisher
Jun 11, 2026

SNDX6417984 Bond Coupon Analysis — Rate & Payments - TradingView

Jun 11, 2026
pulisher
Jun 10, 2026

Syndax Pharmaceuticals (NASDAQ: SNDX) issues $250M 2.25% convertible notes due 2031 - Stock Titan

Jun 10, 2026
pulisher
Jun 10, 2026

Syndax (NASDAQ: SNDX) investors back 2026 equity plan and new ESPP - Stock Titan

Jun 10, 2026
pulisher
Jun 10, 2026

Syndax Pharmaceuticals, Inc. Bonds — Corporate Bond Rates - TradingView

Jun 10, 2026
pulisher
Jun 10, 2026

Syndax Pharmaceuticals Inc Bonds — Corporate Bond Rates - TradingView

Jun 10, 2026
pulisher
Jun 09, 2026

Syndax Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:SNDX) - MarketBeat

Jun 09, 2026
pulisher
Jun 09, 2026

SNDX6417984 Bond Analysis — Key Metrics - TradingView

Jun 09, 2026
pulisher
Jun 08, 2026

Transcript : Syndax Pharmaceuticals, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-08-2026 02 - marketscreener.com

Jun 08, 2026
pulisher
Jun 08, 2026

SNDX: Revuforj's clinical success and expanding pipeline drive growth, with new capital fueling future innovation - TradingView

Jun 08, 2026
pulisher
Jun 08, 2026

Syndax Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus

Jun 08, 2026
pulisher
Jun 07, 2026

SNDX6417984 Bond Price and Chart — FINRA:SNDX6417984 - TradingView

Jun 07, 2026
pulisher
Jun 06, 2026

Price-Driven Insight from (SNDX) for Rule-Based Strategy - Stock Traders Daily

Jun 06, 2026
pulisher
Jun 06, 2026

A Look At Syndax Pharmaceuticals (SNDX) Valuation After Recent Share Price Weakness - Sahm

Jun 06, 2026
pulisher
Jun 05, 2026

Syndax Pharmaceuticals prices $250M senior convertible notes - MSN

Jun 05, 2026
pulisher
Jun 05, 2026

Syndax Pharmaceuticals prices $250 million convertible notes By Investing.com - Investing.com Australia

Jun 05, 2026
pulisher
Jun 04, 2026

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times

Jun 04, 2026
pulisher
Jun 04, 2026

Syndax (SNDX) Launches $250M Convertible Senior Note Offering - GuruFocus

Jun 04, 2026
pulisher
Jun 04, 2026

Syndax Pharmaceuticals (SNDX) Faces Selling Pressure, Testing Near-Term Support LevelsLiquidity Order Flow - newsline.com

Jun 04, 2026
pulisher
Jun 04, 2026

Syndax Pharmaceuticals prices $250 million convertible notes - Investing.com UK

Jun 04, 2026
pulisher
Jun 04, 2026

Goldman Sachs Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $34 - Moomoo

Jun 04, 2026
pulisher
Jun 04, 2026

Syndax Pharmaceuticals Prices $250 Million Convertible Senior Notes - TipRanks

Jun 04, 2026
pulisher
Jun 04, 2026

Syndax Prices $250 Million 2.25% Convertible Notes Due 2031 in Private Placement - TradingView

Jun 04, 2026
pulisher
Jun 04, 2026

Syndax (NASDAQ: SNDX) raises $250M via 2.25% convertible notes due 2031 - Stock Titan

Jun 04, 2026
pulisher
Jun 04, 2026

Syndax Pharmaceuticals Announces $250 Million Private Placement of Convertible Senior Notes - Quiver Quantitative

Jun 04, 2026
pulisher
Jun 04, 2026

Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes - The Manila Times

Jun 04, 2026
pulisher
Jun 04, 2026

Syndax lines up $250M in 2.25% debt swappable into its stock - Stock Titan

Jun 04, 2026
pulisher
Jun 03, 2026

H.C. Wainwright reiterates Syndax Pharmaceuticals stock rating on ASCO data - Investing.com Canada

Jun 03, 2026
pulisher
Jun 03, 2026

Stifel reiterates Syndax Pharmaceuticals stock rating on ASCO data By Investing.com - Investing.com Canada

Jun 03, 2026
pulisher
Jun 02, 2026

Syndax (SNDX) CFO sells 1,177 shares to cover RSU tax withholding - Stock Titan

Jun 02, 2026
pulisher
Jun 02, 2026

Syndax Pharmaceuticals (SNDX) CEO sells shares to cover tax obligations - Stock Titan

Jun 02, 2026
pulisher
Jun 02, 2026

Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data - The Manila Times

Jun 02, 2026
pulisher
Jun 02, 2026

Small leukemia study finds 90% 2-year survival with revumenib after transplant - Stock Titan

Jun 02, 2026
pulisher
Jun 01, 2026

Syndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026 - The Manila Times

Jun 01, 2026

Syndax Pharmaceuticals Inc (SNDX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Syndax Pharmaceuticals Inc (SNDX) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Botwood Nicholas A.J.
Head of R&D, CMO
Jun 11 '26
Option Exercise
13.82
22,515
311,157
95,165
Botwood Nicholas A.J.
Head of R&D, CMO
Jun 11 '26
Sale
18.00
34,280
617,040
60,885
Botwood Nicholas A.J.
Head of R&D, CMO
Jun 12 '26
Sale
18.14
31,235
566,603
60,885
$30.41
price up icon 1.27%
$55.40
price up icon 6.27%
$89.50
price down icon 1.43%
$54.21
price down icon 0.11%
ONC ONC
$263.92
price down icon 1.60%
$156.58
price down icon 2.17%
大文字化:     |  ボリューム (24 時間):